Search the Newsreel

Progyny, Inc. (PGNY) Stock Analysis: Unpacking Growth Potential With A 7.83% Upside

Progyny, Inc. (PGNY) is a healthcare company focused on fertility, family building, and women's health benefits, currently trading at $31.53. The company shows strong financial health with a 14.94% return on equity and over $200 million in free cash flow, reinvesting profits instead of …

Progyny Inc (PGNY) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Progyny Inc (PGNY), highlighting its current earnings forecast score of 8.55 and a "Buy" analyst rating from 11 analysts. It details the average price target of $29.50, with a high of $33.00 and a low of $26.00, …

Earnings Preview: Progyny to Report Financial Results Post-market on August 06

Progyny (PGNY) is scheduled to release its financial results after the market closes on August 6th. The company is expected to report earnings of $0.05 per share, representing a 25% year-over-year increase, with revenue projected to rise 20.3% to $225.4 million. Investors will be …

Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Wall Street expects a year-over-year increase in earnings on higher revenues when Progyny (PGNY) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

PGNY|Progyny Inc|Price:31.360|Chg%:+0.600

This article from TradingKey provides a comprehensive stock analysis of Progyny Inc (PGNY), highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts. It notes that the company is fairly valued with high institutional ownership, although its technical performance doesn't fully support …

Progyny Number of Employees 2026 | Employee Count & Headcount Data

Progyny, Inc. (NASDAQ: PGNY) has approximately 866 total employees worldwide as of March 2026, marking a 53.8% growth from 563 employees in 2023. The company is actively hiring, though job postings declined by 23.9% in 2026. Most of its workforce is concentrated in the …

Progyny (NASDAQ:PGNY): An Affordable Growth Play With Double-Digit Earnings Expansion

Progyny (NASDAQ:PGNY) is presented as an affordable growth opportunity due to its double-digit earnings expansion and reasonable valuation compared to its industry peers. The company demonstrates strong financial health with no debt and high profitability, operating in the growing fertility benefits management sector. While …

Progyny Inc (PGNY) Institutional Confidence

Progyny Inc (PGNY) received an institutional shareholding score of 10.00, placing it first in its industry. The institutional shareholding proportion increased by 8.18% quarter-over-quarter, reaching 113.05%. ETHSX is the largest institutional shareholder, holding 1.05M shares and increasing its holdings by 992.57%.

Barclays downgrades Progyny stock rating on utilization concerns

Barclays has downgraded Progyny (NASDAQ:PGNY) to Equalweight from Overweight despite raising its price target to $34.00, citing concerns about easing utilization trends in fertility clinics based on proprietary website traffic analysis. The analysis showed a deceleration in website traffic growth, suggesting potential headwinds, although …

Progyny Inc (PGNY) Balance Sheet

This article provides the detailed quarterly and annual balance sheets for Progyny Inc (PGNY), including financial data for assets, liabilities, and shareholders' equity across multiple fiscal quarters and years. It also includes an FAQ section defining key balance sheet metrics, differences between assets, liabilities, …

Progyny Inc (PGNY) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Progyny Inc (PGNY) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. Key financial data like market cap and P/E ratio are also …

PGNY|Progyny Inc|Price:31.190|Chg%:+0.490

This article provides an in-depth analysis of Progyny Inc. (PGNY), highlighting its strong fundamentals, high growth potential, and relatively fair valuation. It notes that institutional ownership is high and analysts widely rate the stock as a "Buy" with an upward trend expected in the …

Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report

Progyny, Inc. (Nasdaq: PGNY) will release its second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. The company will host a conference call at 4:45 p.m. Eastern Time on the same day to discuss the results. An audio replay …

Progyny to report Q2 results after market close Aug. 6, host conference call

Progyny (PGNY) is scheduled to release its second-quarter 2026 financial results after the market closes on August 6, 2026. Following the earnings release, the company will host a conference call and webcast at 4:45 p.m. ET to discuss the results. An audio replay of …

A 4:45 p.m. ET webcast will follow Progyny’s Aug. 6 results

Progyny (Nasdaq: PGNY) is scheduled to report its Q2 2026 financial results after market close on Thursday, August 6, 2026. A conference call will follow at 4:45 p.m. Eastern Time, and interested participants can access it via phone or live webcast on Progyny’s investor …

Leerink Partners Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $38

Leerink Partners has reiterated its Buy rating for Progyny (PGNY.US) and set a target price of $38. This indicates the firm's continued confidence in the company's financial prospects and stock performance.

Pinnacle Fertility New York Now Accepts Progyny Benefits, Expanding Access to Fertility Care

Pinnacle Fertility announced that its New York practice, formerly Genesis Fertility, now accepts Progyny benefits, significantly broadening access to comprehensive reproductive care in the New York metropolitan area. This expansion allows eligible Progyny members access to a wide range of physician-led fertility services. This …

PGNY Maintained by Canaccord Genuity -- Price Target Raised to $36

Canaccord Genuity has maintained a "Buy" rating for Progyny (PGNY) and raised its price target to $36.00, reflecting increased confidence in the healthcare company's business model, particularly in fertility and family-building benefits. Despite the positive outlook and a high GF Score™ of 94/100, the …

Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investors

Progyny's COO, Melissa B. Cummings, sold 3,437 shares of common stock worth approximately $109,000 on July 14, 2026. This transaction, which reduced her direct holdings by 5%, was conducted as part of a pre-established Rule 10b5-1 trading plan and for tax obligations. The article …

Progyny COO Melissa B. Cummings disposes of common shares worth $109,393.58

Progyny COO Melissa B. Cummings reduced her common stock holdings by disposing of 3,437 shares in transactions totaling $109,393.58 on July 14, 2026. This included selling 2,244 shares under a Rule 10b5-1 plan and withholding 1,193 shares for tax obligations related to restricted stock …

Form 4 Progyny Inc For: 16 July By Investing.com

This article is a brief financial report titled "Form 4 Progyny Inc For: 16 July

Progyny, Inc. (PGNY) COO trades stock: 2,244 shares sold, 1,193 for taxes

Progyny, Inc.'s Chief Operating Officer, Melissa B. Cummings, reported insider transactions including the sale of 2,244 shares at $31.60 each under a pre-arranged Rule 10b5-1 trading plan. Additionally, 1,193 shares were disposed of to cover withholding taxes related to the vesting of restricted stock …

Progyny stock hits 52-week high at 32.59 USD

Progyny Inc. (PGNY) has reached a 52-week high of $32.59, marking a 102% surge from its 52-week low and a 40.55% 1-year change, indicating strong investor confidence. Despite this, InvestingPro analysis suggests the company may be undervalued, and it recently authorized a $200 million …

Progyny (PGNY) Stock May Be 50% Undervalued On Fresh Analyst Upgrades

Progyny (PGNY): Buy, Sell, or Hold Post Q1 Earnings?

What Progyny (PGNY)'s Governance Shift And $200 Million Buyback Mean For Shareholders

Progyny Buyback Raises Questions On Capital Returns And Growth Plans

Progyny (PGNY) Is Up 7.0% After Analyst Upgrade Backed By Six Earnings Beats And 2026 Outlook

The Strong Earnings Posted By Progyny (NASDAQ:PGNY) Are A Good Indication Of The Strength Of The Business

The Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance Concerns

Earnings call transcript: Progyny Q1 2026 beats EPS forecast, stock dips

Progyny to release quarterly results May 7, with call at 4:45 p.m. ET

Progyny (NASDAQ:PGNY) stock performs better than its underlying earnings growth over last year